A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety

Statistics in Medicine

Volumn 28, Issue 18, 2009, Pages 2293-2306

  Kikuchi, Takashi ^a   Gittins, John ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Clinical trials; Cost benefit; Efficacy; Safety; Sample size

Indexed keywords

INFLIXIMAB; PLACEBO;

ARTICLE; BAYES THEOREM; BINOMIAL DISTRIBUTION; CALCULATION; CHI SQUARE DISTRIBUTION; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; IATROGENIC DISEASE; INTESTINE SURGERY; MATHEMATICAL COMPUTING; MEDICAL CARE; METHODOLOGY; MONTE CARLO METHOD; POISSON DISTRIBUTION; PROBABILITY; PUBLIC HEALTH SERVICE; SAMPLE SIZE; SCORING SYSTEM; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; STATISTICAL MODEL; UNSPECIFIED SIDE EFFECT; VARIANCE;

BAYES THEOREM; BIOMETRY; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; LOGISTIC MODELS; MODELS, STATISTICAL; MONTE CARLO METHOD; SAMPLE SIZE;

EID: 69949095120     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3630     Document Type: Article

References (30)

1. Gittins J, Pezeshk H. A behavioral Bayes method for determining the size of a clinical trial. Drug Information Journal 2000; 34:355-363.
2. Gittins J, Pezeshk H. How large should a clinical trial be? The Statistician 2000; 49(2):177-187.
3. Gittins J, Pezeshk H. A decision theoretic approach to sample size determination in clinical trials. Journal of Biopharmaceutical Statistics 2002; 12(4):535-551.
4. Gittins J, Pezeshk H. A fully Bayesian approach to calculating sample sizes for clinical trials with binary responses. Drug Information Journal 2002; 36:143-150.
5. Willan A, O'Brien B. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Economics 1999; 8:203-211.
6. Garduber J, Huebner M, Jetton J. Power and sample size assessments for tests of hypotheses on cost-effectiveness ratios. Health Economics 2000; 9:227-234.
7. Briggs A, Gray A. Sample size and power calculation for stochastic cost-effectiveness analysis. Medical Decision Making 1998; 18:S81-S92.
8. Laska E, Meisner M, Siegel C. Power and sample size in cost-effectiveness analysis. Medical Decision Making 1999; 19:339-343.
9. Kikuchi T, Pezeshk H, Gittins J. A Bayesian cost-benefit approach to the determination of sample size in clinical trials. Statistics in Medicine 2008; 27(1):68-82. Published online 13th June, 2007.
10. Spiegelhalter D, Freedman L. A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. Statistics in Medicine 1986; 5:1-13.
11. Hutton J, Owens R. Bayesian sample size calculation and prior beliefs about child sexual abuse. The Statistician 1993; 42:399-404.
12. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Economics 1996; 5:513-524.
13. Joseph L, du Berger R, Belisle P. Bayesian and mixed bayesian likelihood criteria for sample size determination. Statistics in Medicine 1997; 16:769-781.
14. Lee S, Zelen M. Clinical trials and sample size considerations: another perspective. Statistical Science 2000; 15:95-103.
15. Brutti P, De Santis F, Gubbiotti S. Robust Bayesian sample size determination in clinical trials. Statistics in Medicine 2008; 27:2290-2306.
16. Wang M, Gelfand A. A simulation-based approach to Bayesian sample size determination for performance under a given model and for separating models. Statistical Science 2002; 17(2):193-208.
17. Patel N, Ankolekar S. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drug and portfolios of drugs. Statistics in Medicine 2007; 26:4976-4988.
18. Bernardo J, Smith A. Bayesian Theory (Wiley Series in Probability and Statistics). Wiley: Chichester, 1994.
19. Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clinical and Experimental Immunology 2005; 139:2-10.
20. Olsson A, Pears J, Mckellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. The American Journal of Cardiology 2001; 88:504-508.
21. Davidson M, Ma P, Stein E, Gotto A, Raza A, Chitra R, Hutchinson H. Comparison of effect on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with Rosuvastatin versus Atorvastatin in patients with type IIa or IIb hypercholesterolemia. The American Journal of Cardiology 2002; 89:268-275.
22. Saito Y, Goto Y, Dane A, Strutt K, Roza A. Randomized dose-response study of Rosuvastatin in Japanese patients with hypercholesterolemia. Journal of Atherosclerosis and Thrombosis 2003; 10(6):329-336.
23. Targan S, Hanauer S, van Deventer S, Mayer L, Present D, Braakman T, DeWoody K, Schaible T, Rutgeertes P, the Crohn's Disease cA2 Study Group F. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. The New England Journal of Medicine 1997; 337:1029-1035.
24. O'Hagan A. Kendall's Advanced Theory of Statistics: Bayesian Inference. Arnold: London, 1994.
25. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117(4):761-769.
26. Bassi A, Dodd S, Bodger K. Cost of illness of inflammatory bowel disease in the U.K.: a single centre retrospective study. Gut 2004; 53:1471-1478.
27. Clark W, Burls A, Song F, Raftery J, Barton P, Cummins C, Fry-Smith A. Infliximab for the treatment of Crohn's disease. 2001. Available from: http://www.nice.org.uk/pdf/FinalreportrevisedEconomicAlalysissection.pdf.
28. Press Release: HUMIRA (adalimumab) receives FDA approval for treatment of Crohn's disease. 2007. Available from: http://www.abbott.com/global/ url/pressRelease/enUS/60.5:5/PressRelease0428.htm.
29. Clinical operations: Accelerating trials, allocating resources and measuring performance. 2006. Available from: http://www.ClinicalTrialBenchmarking.com.
30. Present D, Rutgeerts P, Targan S, Hanauer S, Mayer L, Van Hogezand R, Podolsky D, Sand B, Braakman T, DeWoody K et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. The New England Journal of Medicine 1999; 340(18):1398-1405.